Product nameHuman CBR1 knockout A549 cell lysate
Access thousands of knockout cell lysates, generated from commonly used cancer cell lines.
See here for more information on knockout cell lysates.
User storage instructions: After reconstitution, store the lysate at -80°C.
Parental Cell LineA549
Mutation descriptionKnockout achieved by using CRISPR/Cas9, 1 bp insertion in exon1.
Knockout validationSanger Sequencing, Western Blot (WB)
Reconstitution notesTo use as WB control, resuspend the lyophilizate in 50 µL of LDS* Sample Buffer to have a final concentration of 2 mg/ml. For reducing conditions, we recommend a final concentration of 0.1 M DTT.
*Usage of SDS sample buffer is not recommended with these lyophilized lysates.
Abcam has not and does not intend to apply for the REACH Authorisation of customers’ uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.
Tested applicationsSuitable for: WBmore details
Storage instructionsStore at -80°C. Please refer to protocols.
Components 1 kit ab262241 - Human CBR1 knockout A549 cell lysate (Lyophilized) 1 x 100µg ab255554 - Human Wild Type A549 cell lysate (Lyophilized) 1 x 100µg
STR AnalysisAmelogenin X,Y D5S818: 11 D13S317: 11 D7S820: 8, 11 D16S539: 11, 12 vWA: 14 TH01: 8,9.3 TPOX: 8,11 CSF1PO: 10, 12
FunctionNADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. Catalyzes the reduction of the antitumor anthracyclines doxorubicin and daunorubicin to the cardiotoxic compounds doxorubicinol and daunorubicinol. Can convert prostaglandin E2 to prostaglandin F2-alpha. Can bind glutathione, which explains its higher affinity for glutathione-conjugated substrates. Catalyzes the reduction of S-nitrosoglutathione.
Sequence similaritiesBelongs to the short-chain dehydrogenases/reductases (SDR) family.
- Information by UniProt
- 15 hydroxyprostaglandin dehydrogenase [NADP+]
- 15-hydroxyprostaglandin dehydrogenase [NADP+]
- Carbonyl reductase [NADPH] 1
KO cell lines
Our Abpromise guarantee covers the use of ab257874 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use at an assay dependent concentration. Predicted molecular weight: 30 kDa.|
Lane 1: Wild-type A549 cell lysate (20 ug)
Lane 2: CBR1 knockout A549 cell lysate (20 ug)
Lane 3: HeLa cell lysate (20 ug)
ab156590 Anti-CBR1 antibody [EPR9660] was shown to specifically react with CBR1 in wild-type A549 cells. Loss of signal was observed when knockout cell line ab266954 (knockout cell lysate ab257874) was used. Wild-type and CBR1 knockout samples were subjected to SDS-PAGE. ab156590 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) were incubated overnight at 4°C at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
Homozygous: 1 bp insertion in exon1
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab257874 has not yet been referenced specifically in any publications.